Preclinical and clinical assessment of immune checkpoint inhibitor-associated left ventricular dysfunction
Left ventricular global longitudinal strain reduction in patients with melanoma and extracardiac immune-related adverse events during immune checkpoint inhibitor therapy
Immune-associated Myocarditis in Patients Receiving Camrelizumab -A single-center retrospective study
Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) inhibitors and adverse cardiovascular events: A population-based study